Related references
Note: Only part of the references are listed.PARP inhibitors as antitumor agents: a patent update (2013-2015)
Zigao Yuan et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2017)
Discovery of 2-substituted 1H-benzo[d]immidazole-4-carboxamide derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors with in vivo anti-tumor activity
Jie Zhou et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
FDA approves PARP inhibitor for ovarian cancer
Emily Waltz
NATURE BIOTECHNOLOGY (2017)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
Discovery of novel quinazoline-2,4(1H,3H)-dione derivatives as potent PARP-2 selective inhibitors
Hailong Zhao et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
PARP Inhibitors in Reproductive System Cancers: Current Use and Developments
Geraldine O'Sullivan Coyne et al.
DRUGS (2017)
Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent
Bing Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy
Ying-Qing Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors
Haiping Yao et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2015)
Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy
Gianluca Papeo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Development and validation of high-throughput screening assays for poly(ADP-ribose) polymerase-2 inhibitors
Zhixiang Zhu et al.
ANALYTICAL BIOCHEMISTRY (2014)
PARP inhibitors for anticancer therapy
Nicola Curtin
BIOCHEMICAL SOCIETY TRANSACTIONS (2014)
Applying Synthetic Lethality for the Selective Targeting of Cancer
Donal P. McLornan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Molecular Pathways: Targeting PARP in Cancer Treatment
Khanh Do et al.
CLINICAL CANCER RESEARCH (2013)
BMN673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
Yuqiao Shen et al.
CLINICAL CANCER RESEARCH (2013)
Putting poly (ADP-ribose) polymerase and other DNA repair inhibitors into clinical practice
Thomas Helleday
CURRENT OPINION IN ONCOLOGY (2013)
The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art
Mike De Vos et al.
BIOCHEMICAL PHARMACOLOGY (2012)
A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
Shivaani Kummar et al.
CLINICAL CANCER RESEARCH (2012)
Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699
R. A. Daniel et al.
BRITISH JOURNAL OF CANCER (2010)
Genomic instability - an evolving hallmark of cancer
Simona Negrini et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and-2 Mutant Tumors
Philip Jones et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the Treatment of Cancer
Thomas D. Penning et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
Keith A. Menear et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial
Huw D. Thomas et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling
J Ishida et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2006)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
An enzymatic assay for poly(ADP-ribose) polymerase-1 (PARP-1) via the chemical quantitation of NAD+:: application to the high-throughput screening of small molecules as potential inhibitors
KS Putt et al.
ANALYTICAL BIOCHEMISTRY (2004)
The therapeutic potential of poly(ADP-ribose) polymerase inhibitors
L Virág et al.
PHARMACOLOGICAL REVIEWS (2002)
Share Paper
